Taiwan Bio Therapeutics , Ltd Profit Margin

As of the most recent data (June 2025), 6892.TWO shows a profit margin of -396.79%. That compares with -226.62% in the prior-year period — down 75.1% year over year. That is below the Healthcare sector average of 9.48%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6892.TWO's profit margin is now -396.79% (was -226.62%) — a 75.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Taiwan Bio Therapeutics , Ltd is outperforming or lagging.

The Healthcare sector average profit margin is about 9.48%. Taiwan Bio Therapeutics , Ltd is at -396.79%, which is lower that average. That is roughly 4285.1% below the sector mean. Use the comparison chart on this page to see how 6892.TWO stacks up against individual peers as well.

That compares with -226.62% in the prior-year period — down 75.1% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Taiwan Bio Therapeutics , Ltd with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Taiwan Bio Therapeutics , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -396.79%) with ownership activity and broader fundamentals.